



Figure 1

*Radioligand binding results (IC_{50} values)
for certain compounds of the present invention*



3


IC_{50} values
 D_{2L} (human) < 500 nM
 $D_{4.4}$ (human) > 1 μ M
 $5HT_{1A}$ (human) < 500 nM
 $5HT_{2A}$ (human) < 100 nM
 $5HT_{2B}$ (human) < 100 nM
 $5HT_{2C}$ (human) < 100 nM
 $alpha_{1A}$ (rat) < 100 nM
 $alpha_{1D}$ (human) < 100 nM
 $alpha_{2A}$ (human) < 1 μ M

4

IC_{50} values
 D_{2L} (human) < 500 nM
 $5HT_{2A}$ (human) < 100 nM
 $5HT_{2B}$ (human) < 10 nM
 $5HT_{2C}$ (human) < 500 nM

Figure 2


*Radioligand binding results (IC_{50} values)
for certain compounds of the present invention*



5

IC_{50} values

D_{2L} (human) < 5 μM
 5HT_{2A} (human) < 10 nM
 5HT_{2B} (human) < 10 nM
 5HT_{2C} (human) < 10 nM





6

IC_{50} values

D_{2L} (human) < 5 μM
 5HT_{2A} (human) < 10 nM
 5HT_{2B} (human) < 100 nM
 5HT_{2C} (human) < 10 nM

Figure 3

*Radioligand binding results (IC_{50} values)
for certain compounds of the present invention*



7



IC_{50} values
 D_{2L} (human) > 1 μ M
 D_3 (human) < 1 μ M
 $5HT_1$ (rat) > 1 μ M
 $5HT_{1A}$ (human) < 500 nM
 $5HT_2$ (rat) < 100 nM
 $5HT_{2A}$ (human) < 10 nM
 $5HT_{2B}$ (human) < 100 nM
 $5HT_{2C}$ (human) < 100 nM

8

IC_{50} values
 D_{2L} (human) < 1 μ M
 D_3 (human) < 1 μ M
 $5HT_1$ (rat) > 1 μ M
 $5HT_{1A}$ (human) < 1 μ M
 $5HT_2$ (rat) < 100 nM
 $5HT_{2A}$ (human) < 10 nM
 $5HT_{2B}$ (human) < 100 nM
 $5HT_{2C}$ (human) < 10 nM

Figure 4

*Radioligand binding results (IC_{50} values)
for certain compounds of the present invention*



9


IC_{50} values
 D_{2L} (human) < 1 μ M
 D_3 (human) < 500 nM
 $D_{4.4}$ (human) > 1 μ M
 $5HT_{1A}$ (human) < 500 nM
 $5HT_{2A}$ (human) < 500 nM
 $5HT_{2B}$ (human) < 100 nM
 $5HT_{2C}$ (human) < 500 nM
 $5HT_6$ (human) > 1 μ M
 α_{1A} (rat) < 1 μ M
 α_{1D} (human) > 1 μ M
 α_{2A} (human) > 1 μ M

11

IC_{50} values
 D_{2L} (human) < 1 μ M
 D_{2S} (human) < 1 μ M
 D_3 (human) < 1 μ M
 $D_{4.4}$ (human) > 1 μ M
 $5HT_2$ (rat) > 1 μ M
 $5HT_3$ (human) > 1 μ M
 $5HT_6$ (human) > 1 μ M
 $5HT_7$ (human) < 1 μ M

Figure 5


*Radioligand binding results (IC_{50} values)
for certain compounds of the present invention*



13

IC_{50} values

D_{2L} (human) < 500 nM
 $5HT_{2A}$ (human) < 100 nM
 $5HT_{2B}$ (human) < 100 nM
 $5HT_{2C}$ (human) < 500 nM
 α_{1A} (rat) > 1 μ M
 α_{1D} (human) < 500 nM
 α_{2A} (human) < 1 μ M




14

IC_{50} values

D_{2L} (human) < 500 nM
 $5HT_{2A}$ (human) < 500 nM
 $5HT_{2B}$ (human) < 100 nM
 $5HT_{2C}$ (human) < 500 nM
 α_{1A} (rat) < 100 nM
 α_{1D} (human) < 100 nM
 α_{2A} (human) < 1 μ M

Figure 6


*Radioligand binding results (IC₅₀ values)
for certain compounds of the present invention*



15

IC₅₀ values

NE Transporter (human) <500 nM
D_{2L} (human) <500 nM
D₃ (human) <500 nM
DA Transporter (human) <100 nM
5-HT₇ (human) <500 nM
5-HT Transporter (human) >1 μM



16

IC₅₀ values

alpha 1 (rat) <1 μM
alpha 2 (rat) <1 μM
D_{2L} (human) <1 μM
D_{2S} (human) >1 μM
D₃ (human) <1 μM
D_{4,4} (human) >1 μM
5-HT₇ (human) <1 μM
5-HT_{2A} (human) <1 μM